56 related articles for article (PubMed ID: 1530676)
1. Pharmacokinetics of a sustained release formulation of pyridoxal phosphate of buflomedil after single or repeated oral doses in healthy volunteers.
de Bernardi di Valserra M; Germogli R; Feletti F; Covini D; Borgonovo E
Arzneimittelforschung; 1992 May; 42(5):632-6. PubMed ID: 1530676
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a sustained-release dosage form of clomipramine.
Herrera D; Mayet L; Galindo MC; Jung H
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1488-93. PubMed ID: 11185671
[TBL] [Abstract][Full Text] [Related]
4. [Bioavailability of new nifedipine preparations in man. 1. Pharmacokinetics of nifedipine in the form of sustained-release tablets].
Lutz D; Pabst G; Dahmen W; Molz KH; Jaeger H
Arzneimittelforschung; 1985; 35(12):1840-2. PubMed ID: 4096741
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of terbutaline given in slow-release tablets.
Nyberg L; Kennedy BM
Eur J Respir Dis Suppl; 1984; 134():119-39. PubMed ID: 6586473
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects.
Raz I; Hussein Z; Samara E; Ben-David J
Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):246-8. PubMed ID: 3410601
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of buflomedil after various dosage forms.
Zecca L; Ferrario P; Pirola R; Reina L; Zambotti F; Zonta N; Lepore AM; Scaglione F; Fraschini F
Arzneimittelforschung; 1989 Apr; 39(4):518-9. PubMed ID: 2751740
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients.
Degen PH; Dieterle W; Schneider W; Theobald W; Sinterhauf U
Xenobiotica; 1988 Dec; 18(12):1449-55. PubMed ID: 3245235
[TBL] [Abstract][Full Text] [Related]
10. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
11. Development and pharmacokinetics of a new sustained-release formulation of diltiazem.
Thiercelin JF; Necciari J; Caplain H; Cournot A; Combes M; Desmolin H; Flouvat B
J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S31-7. PubMed ID: 1706011
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses.
Tröger U; Martens J; Meyer FP; Hoffmann A; Terhaag B
Arzneimittelforschung; 1995 Dec; 45(12):1266-70. PubMed ID: 8595082
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.
Cainazzo MM; Pinetti D; Savino G; Bartiromo M; Forgione A; Bertolini A
Drugs Exp Clin Res; 2005; 31(3):115-21. PubMed ID: 16033250
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of carbinoxamine and phenylephrine from a retard capsule after single and repeated dose administration in healthy subjects.
Stockis A; Deroubaix X; Jeanbaptiste B; Lins R; Allemon AM; Laufen H
Arzneimittelforschung; 1995 Sep; 45(9):1009-12. PubMed ID: 7488301
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism.
Tennezé L; Tarral E; Ducloux N; Funck-Brentano C
Clin Pharmacol Ther; 2002 Aug; 72(2):112-22. PubMed ID: 12189358
[TBL] [Abstract][Full Text] [Related]
17. Steady-state kinetics of sustained-release phenylpropanolamine.
Lönnerholm G; Grahnén A; Lindström B
Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):39-41. PubMed ID: 6698658
[TBL] [Abstract][Full Text] [Related]
18. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
[TBL] [Abstract][Full Text] [Related]
19. [Indomethacin kinetics and urinary excretion of prostaglandin E2 following oral administration of various dosage forms of indomethacin].
Düsing R; Dittrich P; Kukovetz WR; Lehmann K; Kramer HJ
Z Rheumatol; 1983; 42(4):235-41. PubMed ID: 6580789
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels.
van der Vet AP; Drost RH; Kreukniet J; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):423-9. PubMed ID: 6490224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
